
Aphinity trial: New Progress in the treatment of HER2-positive breast cancer
A targeted dual therapy improves the survival of patients with HER2+ breast cancers with lymph node positivity.
A targeted dual therapy improves the survival of patients with HER2+ breast cancers with lymph node positivity.
Le département Qualité de l'H.U.B organisera une série d'événements tout au long de la semaine.
The Haematology Department of the H.U.B. is organising several events for patients and their families
Vous y trouverez un résumé de l’activité scientifique de toutes les unités de l’IJB et son plan stratégique pour aller encore plus loin.
ESGO (European Society of Gynaecological Oncology) for the management of locally advanced ovarian cancers.